Literature DB >> 9593778

Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats.

J Yao1, P Kathpalia, D A Bushinsky, M J Favus.   

Abstract

Hypercalciuria in genetic hypercalciuric stone-forming (GHS) rats is accompanied by intestinal Ca hyperabsorption with normal serum 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] levels, elevation of intestinal, kidney, and bone vitamin D receptor (VDR) content, and greater 1,25(OH)2D3-induced bone resorption in vitro. To test the hypothesis that hyperresponsiveness of VDR gene expression to 1,25(OH)2D3 may mediate these observations, male GHS and wild-type Sprague- Dawley normocalciuric control rats were fed a normal Ca diet (0.6% Ca) and received a single intraperitoneal injection of either 1,25(OH)2D3 (10-200 ng/100 g body wt) or vehicle. Total RNAs were isolated from both duodenum and kidney cortex, and the VDR and calbindin mRNA levels were determined by Northern blot hybridization using specific cDNA probes. Under basal conditions, VDR mRNA levels in GHS rats were lower in duodenum and higher in kidney compared with wild-type controls. Administration of 1,25(OH)2D3 increased VDR gene expression significantly in GHS but not normocalciuric animals, in a time- and dose-dependent manner. In vivo half-life of VDR mRNA was similar in GHS and control rats in both duodenum and kidney, and was prolonged significantly (from 4-5 to > 8 h) by 1,25(OH)2D3 administration. Neither inhibition of gene transcription by actinomycin D nor inhibition of de novo protein synthesis with cycloheximide blocked the upregulation of VDR gene expression stimulated by 1,25(OH)2D3 administration. No alteration or mutation was detected in the sequence of duodenal VDR mRNA from GHS rats compared with wild-type animals. Furthermore, 1,25(OH)2D3 administration also led to an increase in duodenal and renal calbindin mRNA levels in GHS rats, whereas they were either suppressed or unchanged in wild-type animals. The results suggest that GHS rats hyperrespond to minimal doses of 1,25(OH)2D3 by an upregulation of VDR gene expression. This hyperresponsiveness of GHS rats to 1,25(OH)2D3 (a) occurs through an increase in VDR mRNA stability without involving alteration in gene transcription, de novo protein synthesis, or mRNA sequence; and (b) is likely of functional significance, and affects VDR-responsive genes in 1, 25(OH)2D3 target tissues. This unique characteristic suggests that GHS rats may be susceptible to minimal fluctuations in serum 1, 25(OH)2D3, resulting in increased VDR and VDR-responsive events, which in turn may pathologically amplify the actions of 1,25(OH)2D3 on Ca metabolism that thus contribute to the hypercalciuria and stone formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593778      PMCID: PMC508810          DOI: 10.1172/JCI1164

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium stone of renal origin.

Authors:  A HODGKINSON; L N PYRAH
Journal:  Br J Surg       Date:  1958-07       Impact factor: 6.939

2.  The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria.

Authors:  R A Kaplan; M R Haussler; L J Deftos; H Bone; C Y Pak
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

3.  Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria.

Authors:  A E Broadus; K L Insogna; R Lang; A F Ellison; B E Dreyer
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

4.  Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats.

Authors:  N S Krieger; V M Stathopoulos; D A Bushinsky
Journal:  Am J Physiol       Date:  1996-07

5.  The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses.

Authors:  T L Chen; P V Hauschka; S Cabrales; D Feldman
Journal:  Endocrinology       Date:  1986-01       Impact factor: 4.736

6.  Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo.

Authors:  T Naveh-Many; R Marx; E Keshet; J W Pike; J Silver
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor.

Authors:  S Dokoh; C A Donaldson; M R Haussler
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects.

Authors:  F L Coe; M J Favus; T Crockett; A L Strauss; J H Parks; A Porat; C L Gantt; L M Sherwood
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

9.  Analysis of rat vitamin D-dependent calbindin-D28k gene expression.

Authors:  S Varghese; S Lee; Y C Huang; S Christakos
Journal:  J Biol Chem       Date:  1988-07-15       Impact factor: 5.157

10.  Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria.

Authors:  C J Van Den Berg; R Kumar; D M Wilson; H Heath; L H Smith
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

View more
  24 in total

1.  The expression and implication of TRPV5, Calbindin-D28k and NCX1 in idiopathic hypercalciuria.

Authors:  Shaogang Wang; Dongliang Hu; Qilin Xi; Shiqiang Su; Jian Bai; Jihong Liu; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

Review 2.  Bone disease in pediatric idiopathic hypercalciuria.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2012-04-06

3.  Inhibition of microRNA-429 in the renal medulla increased salt sensitivity of blood pressure in Sprague Dawley rats.

Authors:  Qing Zhu; Junping Hu; Lei Wang; Weili Wang; Zhengchao Wang; Pin-Lan Li; Krishna M Boini; Ningjun Li
Journal:  J Hypertens       Date:  2017-09       Impact factor: 4.844

4.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

Review 5.  Idiopathic hypercalciuria and bone health.

Authors:  Laura E Ryan; Steven W Ing
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

6.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

7.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

8.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

Review 9.  New insights into the pathogenesis of idiopathic hypercalciuria.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

10.  Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Authors:  Kevin K Frick; John R Asplin; Murray J Favus; Christopher Culbertson; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.